Symbiox Investment & Trading Company Ltd

Symbiox Investment & Trading Company Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be shut from July 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The specific date for the Board Meeting to consider these financial results will be communicated separately. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Symbiox Investment & Trading Company Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. The board also re-appointed Mr. Akhil Agarwal as Secretarial Auditor and Mrs. Shikha Singhal as Internal Auditor for FY 2026-27. The meeting commenced at 1:30 P.M. and concluded at 02:55 P.M.

Symbiox Investment & Trading Company Ltd's Board of Directors, in its meeting held on May 23, 2026, considered and approved the audited financial results and auditor's report for the quarter and year ended March 31, 2026. The board also approved the Limited Review Report on the financial results for the same period. Additionally, Mr. Akhil Agarwal was re-appointed as Secretarial Auditor and Mrs. Shikha Singhal as Internal Auditor for FY 2026-27.

Symbiox Investment & Trading Company Ltd has announced a Board of Directors meeting scheduled for May 23, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026, along with the limited review report. The board will also consider the appointment of Secretarial and Internal Auditors for the financial year 2026-27.

Symbiox Investment & Trading Company Ltd confirms that Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is not applicable as the company did not raise any funds through Public Issue, Rights Issue, Preferential Issue, QIP etc. during the quarter ended 31st March, 2026.

Symbiox Investment & Trading Company Ltd has announced the closure of its trading window in accordance with Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. The trading window will remain closed from 1 April, 2026 till the completion of 48 hours after the declaration of Audited Financial Results of the Company for the quarter and year ended 31** March, 2026 by the Board of Directors. The date of the Board Meeting for considering the financial results for the quarter and year ended on 31° March, 2026 will be informed in due course.

Symbiox Investment & Trading Company Ltd has confirmed that it did not raise any funds through Public Issue, Rights Issue, Preferential Issue, QIP etc. during the quarter ended 31st December, 2025. Therefore, the statement of Deviation or variation in Public Issue, Rights Issue, Preferential issue, etc under Regulation 32 of SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 for the quarter ended 31st December, 2025 is not applicable to the Company.

The Board of Directors of Symbiox Investment & Trading Co Ltd approved the unaudited financial results for the quarter ended on 31st December, 2025. The meeting was held on 7th February, 2026 and also adopted the Auditor's Limited Review Report. The company has been preparing its financial statements in accordance with Indian Accounting Standards (Ind AS) since 1st April, 2017.

The Board of Directors of Symbiox Investment & Trading Company Ltd. met on 7th February, 2026 to approve the unaudited financial results for the quarter ended on 31st December, 2025. The total revenue from operations was 15,34,00,000 for the quarter. The profit before tax was 6,74,00,000 and the profit after tax was 5,51,00,000. The earnings per share (EPS) was ₹ 10.00. The company has adopted Indian Accounting standards (Ind AS) with effect from 01* April, 2017.

Symbiox Investment & Trading Company Ltd has announced a Board of Directors meeting on 7th February 2026. The agenda includes the consideration and approval of the unaudited financial results for the quarter ended on 31st December 2025, as well as the review report on these results. Any other matter with the permission of the Chairperson will also be discussed.